Premium
New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis
Author(s) -
Shioda Yoko,
Sakamoto Kenichi,
Morimoto Akira
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18308
Subject(s) - neurodegeneration , biomarker , langerhans cell histiocytosis , medicine , clinical trial , histiocytosis , disease , biology , genetics
Summary Neurodegeneration in Langerhans cell histiocytosis (ND‐LCH) is a major clinical issue requiring urgent resolution. Sveijer et al. showed that plasma neurofilament light protein is a promising biomarker for screening patients with ND‐LCH and determining the therapeutic effect of a mitogen‐activated protein kinase inhibitor. Therefore, this can be a powerful tool for conducting clinical trials for ND‐LCH. Commentary on: Sveijer M, von Bahr Greenwood T, Jädersten M, Kvedaraite E, Zetterberg H, Blennow K, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198:722–729